Cambrex acquires leading EU stability storage company Q1 Scientific

Published: 1-Jun-2022

Stability storage and testing is a critical component of drug development and commercialisation of new therapies

Cambrex, a leading global contract development and manufacturing organisation (CDMO) providing drug substance, drug product and analytical services across the entire drug lifecycle, has announced the acquisition of Q1 Scientific — a leading provider of environmentally controlled cGMP stability storage services for the pharmaceutical, medical device and life science industries, strategically located in Waterford, Ireland.

"Q1 Scientific brings world-class capabilities to our ever-expanding portfolio of outsourced pharmaceutical services," said Tom Loewald, CEO, Cambrex. "This acquisition is a natural extension of our current offerings that will broaden and increase our expertise in this critical area, as well as our footprint in the European market."

Q1 Scientific's state-of-the-art cGMP facility is ICH validated to meet the specific storage requirements of any pharmaceutical project, with options from -80 °C storage up to +50 °C, with a full range of humidity control.

The 20,000 ft2 Waterford facility boasts nearly 40 walk-in stability storage chambers, reach-in freezers and stability units, and ultra-low temperature freezers for biologic therapies. The company also provides sample management and transport services.

"We're pleased to join Cambrex as we continue to provide leading stability storage services to our current customers," said Stephen Delaney, CEO, Q1 Scientific.

"With Cambrex's scientific expertise and scale, we'll be able to accelerate our growth and offer an integrated suite of analytical services, providing a full range of market-leading solutions for our customers."

Cambrex offers a variety of storage and testing capabilities with walk-in and reach-in chambers that meet the ICH Q1A requirements. The acquisition will expand Cambrex's capabilities into the European market.

As pharmaceutical and biopharmaceutical companies continue to seek outsourcing options for non-core capabilities to reduce their footprint, Q1 Scientific's stability storage services, combined with Cambrex's industry leading analytical services portfolio, provide specialized capabilities of high value to the industry.

You may also like